Other strategies focus on modulating the activation of CD8+ T cells by targeting co-stimulatory molecules such as CD28 or CTLA-4, with the use of abatacept in RA demonstrating reduced CD8+ T cell activation and inflammation [39]. The gene discussed is CD8A; the disease is rheumatoid arthritis.